메뉴 건너뛰기




Volumn 3, Issue 1, 1998, Pages 4-10

Clinical guidelines for managing topotecan-related hematologic toxicity

Author keywords

Chemotherapy; Ovarian cancer; Topoisomerase I inhibitor; Topotecan

Indexed keywords

CAMPTOTHECIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOMYCIN C; NITROSOUREA DERIVATIVE; TOPOTECAN;

EID: 0031931277     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.3-1-4     Document Type: Article
Times cited : (71)

References (21)
  • 1
    • 0027323646 scopus 로고
    • Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony stimulating factors
    • Saltz L, Sirott M, Young C et al. Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony stimulating factors. J Natl Cancer Inst 1993;85:1499-1507.
    • (1993) J Natl Cancer Inst , vol.85 , pp. 1499-1507
    • Saltz, L.1    Sirott, M.2    Young, C.3
  • 2
    • 0027454410 scopus 로고
    • Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor
    • Verweij J, Lund B, Beijnen J et al. Phase I and pharmacokinetic study of topotecan, a new topoisomerase I inhibitor. Ann Oncol 1993;4:673-678.
    • (1993) Ann Oncol , vol.4 , pp. 673-678
    • Verweij, J.1    Lund, B.2    Beijnen, J.3
  • 3
    • 0026537874 scopus 로고
    • Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
    • Rowinsky EK, Grochow LB, Hendricks CB et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 1992;10:647-656.
    • (1992) J Clin Oncol , vol.10 , pp. 647-656
    • Rowinsky, E.K.1    Grochow, L.B.2    Hendricks, C.B.3
  • 4
    • 0028090410 scopus 로고
    • Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia
    • Rowinsky EK, Adjei AA, Donehower RC et al. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994;12:2193-2203.
    • (1994) J Clin Oncol , vol.12 , pp. 2193-2203
    • Rowinsky, E.K.1    Adjei, A.A.2    Donehower, R.C.3
  • 5
    • 0027501999 scopus 로고
    • Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia
    • Kantarjian HM, Beran M, Ellis A et al. Phase I study of topotecan, a new topoisomerase I inhibitor in patients with refractory or relapsed acute leukemia. Blood 1993;81:1146-1151.
    • (1993) Blood , vol.81 , pp. 1146-1151
    • Kantarjian, H.M.1    Beran, M.2    Ellis, A.3
  • 7
    • 9244247616 scopus 로고    scopus 로고
    • Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma
    • Kudelka AP, Tresukosol D, Edwards CL et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J Clin Oncol 1996;14:1552-1557.
    • (1996) J Clin Oncol , vol.14 , pp. 1552-1557
    • Kudelka, A.P.1    Tresukosol, D.2    Edwards, C.L.3
  • 8
    • 10544229791 scopus 로고    scopus 로고
    • Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
    • Creemers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996:14:3056-3061.
    • (1996) J Clin Oncol , vol.14 , pp. 3056-3061
    • Creemers, G.J.1    Bolis, G.2    Gore, M.3
  • 9
    • 0000391321 scopus 로고    scopus 로고
    • Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International topotecan study group trial
    • Gordon A, Bookman M, Malmstrom H et al. Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: international topotecan study group trial. Proc Am Soc Clin Oncol 1996;15:282.
    • (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 282
    • Gordon, A.1    Bookman, M.2    Malmstrom, H.3
  • 10
    • 0030900145 scopus 로고    scopus 로고
    • Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
    • ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997:15:2183-2193.
    • (1997) J Clin Oncol , vol.15 , pp. 2183-2193
    • Ten Bokkel Huinink, W.1    Gore, M.2    Carmichael, J.3
  • 11
    • 0029934111 scopus 로고    scopus 로고
    • A phase II trial of topotecan in patients with unresectable and untreated pancreatic cancer
    • O'Reilly S, Donehower RC, Rowinsky EK et al. A phase II trial of topotecan in patients with unresectable and untreated pancreatic cancer. Anti-Cancer Drugs 1996;7:410-414.
    • (1996) Anti-Cancer Drugs , vol.7 , pp. 410-414
    • O'Reilly, S.1    Donehower, R.C.2    Rowinsky, E.K.3
  • 12
    • 0000626027 scopus 로고
    • A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer
    • Armstrong D, Rowinsky E, Donehower R et al. A phase II trial of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995;12:275.
    • (1995) Proc Am Soc Clin Oncol , vol.12 , pp. 275
    • Armstrong, D.1    Rowinsky, E.2    Donehower, R.3
  • 13
    • 15844424667 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of topotecan in patients with impaired hepatic function
    • O'Reilly S, Rowinsky EK, Slichenmeyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996;88:817-824.
    • (1996) J Natl Cancer Inst , vol.88 , pp. 817-824
    • O'Reilly, S.1    Rowinsky, E.K.2    Slichenmeyer, W.3
  • 14
    • 0029966916 scopus 로고    scopus 로고
    • Phase I and pharmacologic study of topotecan in patients with impaired renal function
    • O'Reilly S, Rowinsky EK, Slichenmeyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996; 14:3062-3073.
    • (1996) J Clin Oncol , vol.14 , pp. 3062-3073
    • O'Reilly, S.1    Rowinsky, E.K.2    Slichenmeyer, W.3
  • 15
    • 0031456165 scopus 로고    scopus 로고
    • Life threatening myelosuppression in patients with renal impairment receiving topotecan
    • O'Reilly S, Armstrong DK, Grochow LB. Life threatening myelosuppression in patients with renal impairment receiving topotecan. Gynecol Oncol 1997;67:329-330.
    • (1997) Gynecol Oncol , vol.67 , pp. 329-330
    • O'Reilly, S.1    Armstrong, D.K.2    Grochow, L.B.3
  • 16
    • 0024440650 scopus 로고
    • Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
    • Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
    • (1989) J Clin Oncol , vol.7 , pp. 1748-1756
    • Calvert, A.H.1    Newell, D.R.2    Gumbrell, L.A.3
  • 17
    • 0028036827 scopus 로고
    • American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors:evidence based clinical practice guidelines
    • American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors:evidence based clinical practice guidelines. J Clin Oncol 1994; 12:2471-2508.
    • (1994) J Clin Oncol , vol.12 , pp. 2471-2508
  • 18
    • 0344405536 scopus 로고    scopus 로고
    • Update of recommendations for the use of hematopoietic colony stimulating factors: Evidence based clinical practice guidelines
    • American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony stimulating factors: evidence based clinical practice guidelines. J Clin Oncol 1996;14:1957-1960.
    • (1996) J Clin Oncol , vol.14 , pp. 1957-1960
  • 19
    • 0026603461 scopus 로고
    • Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer
    • Jodrell DI, Egorin MJ, Canetta RM et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-528.
    • (1992) J Clin Oncol , vol.10 , pp. 520-528
    • Jodrell, D.I.1    Egorin, M.J.2    Canetta, R.M.3
  • 20
    • 0015674428 scopus 로고
    • Creatinine clearance: Bedside estimate
    • Jeliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-605.
    • (1973) Ann Intern Med , vol.79 , pp. 604-605
    • Jeliffe, R.W.1
  • 21
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.